Takeharu Sakamoto

Dr. Takeharu Sakamoto

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
DRDouglas Rubinson
Douglas Rubinson
TSTakeharu Sakamoto
Takeharu Sakamoto
FCFerran Fece de la Cruz
Ferran Fece de la Cruz
KKKevin S. Kapner
Kevin S. Kapner
MRMichael H. Rosenthal
Michael H. Rosenthal
RCRyan B. Corcoran
Ryan B. Corcoran
KRASG12C inhibitors, like sotorasib and adagrasib, potently and selectively inhibit KRASG12C through a covalent interaction with the mutant cysteine, driving clinical efficacy in KRASG12C tumors. Because amino acid sequences of the three main RAS isoforms—KRAS, NRAS, and HRAS—are highly similar, we hypothesized that some KRASG12C inhibitors might also target NRASG12C and/or HRASG12C, which are less common but critical oncogenic driver mutations in some tumors. Although some inhibitors, like adagrasib, were highly selective for KRASG12C, others also potently inhibited NRASG12C and/or HRASG12C. Notably, sotorasib was five-fold more potent against NRASG12C compared with KRASG12C or HRASG12C. Structural and reciprocal mutagenesis studies suggested that differences in isoform-specific binding are mediated by a single amino acid: Histidine-95 in KRAS (Leucine-95 in NRAS). A patient with NRASG12C colorectal cancer treated with sotorasib and the anti-EGFR antibody panitumumab achieved a marked tumor response, demonstrating that sotorasib can be clinically effective in NRASG12C-mutated tumors. Significance: These studies demonstrate that certain KRASG12C inhibitors effectively target all RASG12C mutations and that sotorasib specifically is a potent NRASG12C inhibitor capable of driving clinical responses. These findings have important implications for the treatment of patients with NRASG12C or HRASG12C cancers and could guide design of NRAS or HRAS inhibitors. See related commentary by Seale and Misale, p. 698. This article is featured in Selected Articles from This Issue, p. 695

31 August 2023 in Cells
Verified
Journal Article
Open access
PDF file
TSTakeharu Sakamoto
Takeharu Sakamoto
TSTakeharu Sakamoto
Takeharu Sakamoto
Membrane type1-matrix metalloproteinase (MT1-MMP) is a member of metalloproteinases that is tethered to the transmembrane. Its major function in cancer progression is to directly degrade the extracellular matrix components, which are mainly type I–III collagen or indirectly type IV collagen through the activation of MMP-2 with a cooperative function of the tissue inhibitor of metalloproteinase-2 (TIMP-2). MT1-MMP is expressed as an inactive form (zymogen) within the endoplasmic reticulum (ER) and receives truncation processing via furin for its activation. Upon the appropriate trafficking of MT1-MMP from the ER, the Golgi apparatus to the cell surface membrane, MT1-MMP exhibits proteolytic activities to the surrounding molecules such as extracellular matrix components and cell surface molecules. MT1-MMP also retains a non-proteolytic ability to activate hypoxia-inducible factor 1 alpha (HIF-1A) via factors inhibiting the HIF-1 (FIH-1)-Mint3-HIF-1 axis, resulting in the upregulation of glucose metabolism and oxygen-independent ATP production. Through various functions of MT1-MMP, cancer cells gain motility on migration/invasion, thus causing metastasis. Despite the long-time efforts spent on the development of MT1-MMP interventions, none have been accomplished yet due to the side effects caused by off-target effects. Recently, MT1-MMP-specific small molecule inhibitors or an antibody have been reported and these inhibitors could potentially be novel agents for cancer treatment.

14 February 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
TSTakeharu Sakamoto
Takeharu Sakamoto
TSTakeharu Sakamoto
Takeharu Sakamoto
Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor that plays a crucial role in cells adapting to a low-oxygen environment by facilitating a switch from oxygen-dependent ATP production to glycolysis. Mediated by membrane type-1 matrix metalloproteinase (MT1-MMP) expression, Munc-18-1 interacting protein 3 (Mint3) binds to the factor inhibiting HIF-1 (FIH-1) and inhibits its suppressive effect, leading to HIF-1α activation. Defects in Mint3 generally lead to improved acute inflammation, which is regulated by HIF-1α and subsequent glycolysis, as well as the suppression of the proliferation and metastasis of cancer cells directly through its expression in cancer cells and indirectly through its expression in macrophages or fibroblasts associated with cancer. Mint3 in inflammatory monocytes enhances the chemotaxis into metastatic sites and the production of vascular endothelial growth factors, which leads to the expression of E-selectin at the metastatic sites and the extravasation of cancer cells. Fibroblasts express L1 cell adhesion molecules in a Mint3-dependent manner and enhance integrin-mediated cancer progression. In pancreatic cancer cells, Mint3 directly promotes cancer progression. Naphthofluorescein, a Mint3 inhibitor, can disrupt the interaction between FIH-1 and Mint3 and potently suppress Mint3-mediated inflammation, cancer progression, and metastasis without causing marked adverse effects. In this review, we will introduce the potential of Mint3 as a therapeutic target for inflammatory diseases and cancers.

1 November 2011 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YMYuri Masuda
Yuri Masuda
KNKohji Noguchi
Kohji Noguchi
HSHatsune Segawa
Hatsune Segawa
TSTakeharu Sakamoto
Takeharu Sakamoto
KKKazuhiro Katayama
Kazuhiro Katayama
YSYoshikazu Sugimoto
Yoshikazu Sugimoto

1 May 2024
Verified
Other
Open access
DRDouglas Rubinson
Douglas Rubinson
TSTakeharu Sakamoto
Takeharu Sakamoto
FCFerran Fece de la Cruz
Ferran Fece de la Cruz
KKKevin S. Kapner
Kevin S. Kapner
MRMichael H. Rosenthal
Michael H. Rosenthal
RCRyan B. Corcoran
Ryan B. Corcoran
KRASG12C inhibitors, like sotorasib and adagrasib, potently and selectively inhibit KRASG12C through a covalent interaction with the mutant cysteine, driving clinical efficacy in KRASG12C tumors. Because amino acid sequences of the three main RAS isoforms—KRAS, NRAS, and HRAS—are highly similar, we hypothesized that some KRASG12C inhibitors might also target NRASG12C and/or HRASG12C, which are less common but critical oncogenic driver mutations in some tumors. Although some inhibitors, like adagrasib, were highly selective for KRASG12C, others also potently inhibited NRASG12C and/or HRASG12C. Notably, sotorasib was five-fold more potent against NRASG12C compared with KRASG12C or HRASG12C. Structural and reciprocal mutagenesis studies suggested that differences in isoform-specific binding are mediated by a single amino acid: Histidine-95 in KRAS (Leucine-95 in NRAS). A patient with NRASG12C colorectal cancer treated with sotorasib and the anti-EGFR antibody panitumumab achieved a marked tumor response, demonstrating that sotorasib can be clinically effective in NRASG12C-mutated tumors.Significance:These studies demonstrate that certain KRASG12C inhibitors effectively target all RASG12C mutations and that sotorasib specifically is a potent NRASG12C inhibitor capable of driving clinical responses. These findings have important implications for the treatment of patients with NRASG12C or HRASG12C cancers and could guide design of NRAS or HRAS inhibitors.See related commentary by Seale and Misale, p. 698.This article is featured in Selected Articles from This Issue, p. 695

1 May 2024
Verified
Other
Open access
PDF file
DRDouglas Rubinson
Douglas Rubinson
TSTakeharu Sakamoto
Takeharu Sakamoto
FCFerran Fece de la Cruz
Ferran Fece de la Cruz
KKKevin S. Kapner
Kevin S. Kapner
MRMichael H. Rosenthal
Michael H. Rosenthal
RCRyan B. Corcoran
Ryan B. Corcoran
Supplementary Figure S1 shows IC50 values of KRASG12C inhibitors for KRASG12C, NRASG12C, HRASG12C.Supplementary Figure S2 shows inhibition of NRASG12C by sotorasib in 293T and MOLT-4 cells.Supplementary Figure S3 shows effect of amino acid substitutions in NRASG12C or KRASG12C on signaling in response to sotorasib and adagrasib.Supplementary Figure S4 who's location of isoform-variable residues relative to Switch-II binders.Supplementary Figure S5 shows crystal structures of KRASG12C inhibitors and interactions with His95.Supplementary Figure S6 shows chemical structures of switch-II pocket-binding KRASG12C inhibitors.Supplementary Figure S7 shows structural model of sotorasib interaction with Leu95.